Jefferies Maintains Buy on Dyne Therapeutics, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Jefferies has maintained its Buy rating on Dyne Therapeutics (NASDAQ:DYN) and raised the price target from $36 to $42.
May 20, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has maintained its Buy rating on Dyne Therapeutics and raised the price target from $36 to $42, indicating strong confidence in the company's future performance.
The raised price target from $36 to $42 by Jefferies suggests a positive outlook for Dyne Therapeutics, likely leading to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100